Repligen Receives $1.4 Million Research Grant from the Muscular Dystrophy Association to Support Spinal Muscular Atrophy Development Program
Repligen Corporation Press Release | December 15, 2010
WALTHAM, Mass., Dec. 15, 2010 /PRNewswire/ — Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association (“MDA”) to support the ongoing development of RG3039 for Spinal Muscular Atrophy (“SMA”). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA. The goal of this grant is to support the advancement of RG3039 into human clinical testing, including continued evaluation in preclinical models of SMA, GMP manufacturing for human clinical trials and early clinical evaluation in healthy volunteers and patients. Funding from the Muscular Dystrophy Association provides important support for Repligen’s development programs and access to a global network of scientists, physicians and patients. Repligen has previously been awarded two research grants from the MDA to support its Friedreich’s ataxia program.
Click HERE or on the image below to read more…